Thais Heinke

Prof. Dr. Thais Heinke

Pathology, UNIFESP, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2007 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
PDF file
EBErika M. Bastos
Erika M. Bastos
MNMiguel S. Neto
Miguel S. Neto
MAMaria Teresa S. Alves
Maria Teresa S. Alves
ÉGÉlvio B. Garcia
Élvio B. Garcia
RSRafael A. Santos
Rafael A. Santos
LFLydia M. Ferreira
Lydia M. Ferreira

17 May 2021 in Menopause
Verified
Journal Article
Closed access
PDPaula Pallone Dutra
Paula Pallone Dutra
Thais HeinkeThais Heinke
Thais Heinke
SPStella Catunda Pinho
Stella Catunda Pinho
GFGustavo Rubino Azevedo Focchi
Gustavo Rubino Azevedo Focchi
FTFernanda Kesselring Tso
Fernanda Kesselring Tso
NSNeila Maria Góis Speck
Neila Maria Góis Speck
Objective: To compare the efficacy of fractional CO2 laser therapy with topical estrogen therapy for the treatment of postmenopausal genitourinary syndrome of menopause. Methods: We conducted a randomized controlled clinical trial involving 25 postmenopausal women. Participants were aged between 50 and 65 years with at least 1 year of amenorrhea and follicle-stimulating hormone levels of >40 IU/L. The women were randomized into two groups: the laser therapy group (n = 13) and the vaginal topical estrogen therapy group (n = 12). Changes in the vaginal epithelium thickness, Frost index, and cell maturation were analyzed in both the groups. The female sexual quotient of each woman was also evaluated. Subjective evaluation was performed through a physical examination. Results: Histological analysis showed a significant increase in the vaginal epithelium thickness at the end of treatment in females in both the laser therapy (P < 0.001) and topical estrogen therapy (P = 0.001) groups. The topical estrogen therapy group tended to present a higher maturation index at the end of treatment when compared with that of the other group. Sexual function increased significantly over time in both the topical estrogen therapy (P < 0.001) and laser therapy (P < 0.001) groups. Subjective evaluation through physical examination showed a significant improvement in atrophy in both the groups. Conclusion: Despite the nonequivalence with topical estrogen therapy, our data suggest that laser therapy is an effective method for the treatment of vulvovaginal atrophy.

1 June 2008 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
Thais HeinkeThais Heinke
Thais Heinke
LPLucila Bohme Pellacani
Lucila Bohme Pellacani
HCHenrique de Oliveira Costa
Henrique de Oliveira Costa
RFRogério Aoki Fuziy
Rogério Aoki Fuziy
MFMarcello Franco
Marcello Franco

1 August 2012 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
JDJuliane Dornelas
Juliane Dornelas
Zsuzsanna Ilona Katalin Jármy-Di BellaZsuzsanna Ilona Katalin Jármy-Di Bella
Zsuzsanna Ilona Katalin Jármy-Di Bella
Thais HeinkeThais Heinke
Thais Heinke
MKMarcio M. Kajikawa
Marcio M. Kajikawa
CTCláudia C. Takano
Cláudia C. Takano
MGManoel J.B.C. Girão
Manoel J.B.C. Girão

1 January 2015 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
MCMary Catherine Cambou
Mary Catherine Cambou
PLPaula M. Luz
Paula M. Luz
JLJordan E. Lake
Jordan E. Lake
JLJosé Eduardo Levi
José Eduardo Levi
JCJosé Ricardo Coutinho
José Ricardo Coutinho
BGBeatriz Grinsztejn
Beatriz Grinsztejn
Identifying factors, including human papillomavirus (HPV) genotypes, associated with abnormal anal cytology in HIV-infected women have implications for anal squamous cell cancer (SCC) prevention in HIV-infected women. Anal and cervical samples were collected for cytology, and tested for high-(HR-HPV) and low-risk HPV (LR-HPV) genotypes in a cross-sectional analysis of the IPEC Women's HIV Cohort (Rio de Janeiro, Brazil). Multivariate log-binomial regression models estimated prevalence ratios for factors associated with abnormal anal cytology [≥ atypical squamous cells of undetermined significance, (ASC-US)]. Characteristics of the 863 participants included: median age 42 years, 57% non-white, 79% current CD4+ T-cell count >350 cells/mm(3), 53% HIV-1 viral load <50 copies/mL, median ART duration 5.8 years. Fifty-one percent of anal specimens contained ≥ 1 HR-HPV genotype; 31% had abnormal anal cytology [14% ASC-US, 11% low-grade squamous intra-epithelial lesion, (LSIL); 2% atypical squamous cells-cannot exclude high-grade SIL (ASC-H); 4% high-grade SIL/cancer (HSIL+)]. In multivariate analysis, cervical LSIL+, nadir CD4+ T-cell count ≤ 50 cells/mm(3), HIV-1 viral load ≥ 50 copies/mL, and anal HPV 6, 11, 16, 18, 33, 45, 52, 56, and 58 were associated with ≥ anal ASC-US (p<0.05). Abnormal anal cytology and HR-HPV prevalences were high. HIV-infected women with cervical LSIL+, low nadir CD4+ counts, or detectable HIV-1 viral loads should be a particular focus for enhanced anal SCC screening efforts.

1 November 2006 in Transplantation Proceedings
Verified
Journal Article
Closed access
CGC. Di Giorno
C. Di Giorno
HPH.S. Pinheiro
H.S. Pinheiro
Thais HeinkeThais Heinke
Thais Heinke
MFM.F. Franco
M.F. Franco
NGN.Z. Galante
N.Z. Galante
NCNiels Olsen Saraiva Camara
Niels Olsen Saraiva Camara